Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of LusiNEX (Mycenax tocilizumab biosimilar)

Next Previous
X
Search
Trial Profile

A phase III study of LusiNEX (Mycenax tocilizumab biosimilar)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 15 Jan 2025 According to a Mochida Pharmaceutical Media Release, trial met its primary endpoint.
    • 15 Jan 2025 Topline results presented in the Mochida Pharmaceutical Media Release.
    • 15 Jan 2025 According to a Gedeon Richter Media Release, based on the positive topline results from the phase 1 and phase 3 studies of RGB-19, Richter expects to file for marketing authorization applications for RGB-19 in major European markets in the coming months, while Mochida expects to file for marketing authorization application for RGB-19 in Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top